Analytical and biological considerations in the measurement of cell-associated CCR5 and CXCR4 mRNA and protein

Clinical and Vaccine Immunology

Volumn 17, Issue 7, 2010, Pages 1148-1154

  Campbell, D E ^a   Lai, J P ^a   Tustin, N B ^a   Riedel, E ^a   Tustin III, R ^a   Taylor, J ^a   Murray, J ^a   Douglas, S D ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EDETIC ACID; MESSENGER RNA;

ACCURACY; ARTICLE; BLOOD SAMPLING; CELL SEPARATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; MEASUREMENT; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; CHEMISTRY; GENETICS; IMMUNITY; PROCEDURES; T LYMPHOCYTE;

FLOW CYTOMETRY; IMMUNITY; METHODS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 77954358609     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00533-09     Document Type: Article

References (17)

1. Berhanu, D., F. Mortari, S. C. DeRosa, and M. Roederer. 2003. Optimized lymphocyte isolation methods for analysis of chemokine receptor expression. J. Immunol. Methods 279:199-207.
2. Cane, P. A. 2009. New developments in HIV drug resistance. J. Antimicrob. Chemother. 64(Suppl. 1):i37-i40.
3. Cardozo, T., T. Kimura, S. Philpott, B. Weiser, H. Burger, and S. Zolla-Pazner. 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses 23:415-426.
4. Chen, T. K., and G. M. Aldrovandi. 2008. Review of HIV antiretroviral drug resistance. Pediatr. Infect. Dis. J. 27:749-751.
5. Croxtall, J. D., and S. J. Keam. 2009. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 69:1059-1075.
6. Gulick, R. M., J. Lalezari, J. Goodrich, N. Clumeck, E. DeJesus, A. Horban, J. Nadler, B. Clotet, A. Karlson, M. Wohlfeiler, J. B. Montana, M. McHale, J. Sullivan, C. Ridgway, S. Felstead, M. W. Dunne, E. van der Ryst, and H. Mayer, for the MOTIVATE Study Teams. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
7. Huang, C.-C., M. Tang, M.-Y. Zhang, S. Majeed, E. Montabana, R. L. Stanfield, D. S. Dimitrov, B. Korber, J. Sodroski, I. A. Wilson, R. Wyatt, and P. D. Kwong. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
8. Kondru, R., J. Zhang, C. Ji, T. Mirzadegan, D. Rotstein, S. Sankuratri, and M. Dioszegi. 2008. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73:789-800.
9. Lai, J.-P., J.-H. Yang, S. D. Douglas, X. Wang, E. Riedel, and W.-Z. Ho. 2003. Quantification of CCR5 mRNA in human lymphocytes and macrophages by real-time reverse transcriptase PCR assay. Clin. Diagn. Lab. Immunol. 10: 1123-1128.
10. Lederman, M. M., A. Penn-Nicholson, M. Cho, and D. Mosfer. 2006. Biology of CCR5 and its role in HIV infection ad treatment. JAMA 296:815-826.
11. Little, S. J., S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
12. Murphy, E. L., A. C. Collier, L. A. Kalish, S. F. Assman, M. F. Para, T. P. Flanigan, P. N. Kumar, L. Mintz, F. R. Wallach, and G. J. Nemo, for the Viral Activation Transfusion Study Investigators. 2001. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:17-26.
13. Ribeiro, R. M., M. D. Hazenberg, A. S. Perelson, and M. P. Davenport. 2006. Naïve and memory cell turnover as drivers of CCR5-to-C4CR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J. Virol. 80:802-809.
14. Rosen, O., M. Sharon, S. R. Quadt-Akabayov, and J. Anglister. 2006. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc. Natl. Acad. Sci. U. S. A. 103:13950-13955.
15. Su, Z., R. M. Gulick, A. Krambrink, E. Coakley, M. D. Hughes, D. Han, C. Flexner, T. J. Wilkin, P. R. Skolnik, W. L. Greaves, D. R. Kuritzkes, J. D. Reeves, and AIDS Clinical Trials Group A5211 Team. 2009. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J. Infect. Dis. 200:1724-1728.
16. Tsibris, A. M. N., and D. R. Kuritzres. 2007. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58:445-459.
17. Yi, L., J. Fang, N. Isik, J. Chim, and T. Jin. 2006. HIV gp120-induced interaction between CD4 and CCR5 requires cholesterol-rich microenvironments revealed by live fluorescence resonance energy transfer imaging. J. Biol. Chem. 281:35446-35453.